Crinetics Pharmaceuticals (CRNX) Tops Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts CRNX Hot Sheet
Join SI Premium – FREE
Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($1.29), $0.05 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $6.1 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Phillips 66, Marathon Merger Talks Collapsed - Semafor
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
